15
Participants
Start Date
September 5, 2025
Primary Completion Date
August 31, 2026
Study Completion Date
September 30, 2026
CYTALUX™ (pafolacianine)
All subjects participating in the study are expected to receive CYTALUX™ (pafolacianine) injection and standard care surgery; 1 to 24 hours after CYTALUX™ (pafolacianine) injection infusion is completed, all tumors planned to be removed as part of standard care will undergo assessment with NIR light imaging both intraoperatively and on the back table following surgery.
RECRUITING
Cedars-Sinai Medical Center, Los Angeles
Collaborators (1)
On Target Laboratories, LLC
INDUSTRY
Cedars-Sinai Medical Center
OTHER